No Increased Risk for MI or Stroke from Atazanavir

DAD results suggest that the association between MI risk and PI exposure is not a classwide phenomenon.

Recently, the DAD study group reported an increased risk for myocardial infarction (MI) in HIV-infected patients with longer duration of antiretroviral therapy containing protease inhibitors (PIs), particularly lopinavir and indinavir (JW AIDS Clin Care Feb 1 2010). However, due to the limited follow-up period at the time of the previous report, the researchers were unable to assess the effects of atazanavir, a PI currently recommended by the Department of Health and Human Services.

Now, to determine the possible risks for MI and stroke associated with cumulative exposure to atazanavir, the DAD investigators have analyzed data contributed by patients who had ever received the drug between 2005 and 2011 (37,005 patient-years of follow-up); 85…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

No Increased Risk for MI or Stroke from Atazanavir

Topics

Reviewing Author